Cinryze

Type: Product
Name: Cinryze
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

PHARM: Is That a Crack Forming in Cinryze’s Universe? Could Be. Reiterate Buy

Biotech company Pharming Group NV announces the analyst report completed by Joseph Pantginis, Ph.D. from Roth Capital Partners is published.Ruconest continues its drive forward with a U.S. launch expected in 4Q14 for acute HAE. Today Pharming and Salix ... [Published Noodls - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

AbbVie: Growth Story Or Patent Expiration Nightmare?

Summary AbbVie's Humira treatment is growing rapidly worldwide, propelling the company's revenue. The company has a strong dividend yield of 3%. AbbVie faces serious questions from patent expirations after 2016.AbbVie (NYSE: ABBV ) is a global biopharmaceutical ... [Published Seeking Alpha - Aug 28 2014]
Entities: AbbVie Inc, Dividend, HUMIRA
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Emerging Pharma Leaders: Susanne Heinzinger

Susanne Heinzinger, Executive Director of Product Strategy and Alliance Management, Achillion Pharmaceuticals.To say that Susanne Heinzinger’s career trajectory has taken her from one spectrum of the healthcare arena to another may be an understatement. ... [Published Pharmaceutical Executive - Aug 14 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

US drugs giant finally seals £32bn takeover of Shire

The FTSE 100 big-pharma player Shire celebrated a £32bn takeover by US suitor AbbVie with record results as the two companies beat a Takeover Panel deadline to agree a firm offer. The UK firm unveiled a 22 per cent rise in quarterly revenues to a record ... [Published The Independent - Jul 19 2014]
First reported May 01 2014 - Updated May 02 2014 - 2 reports

Shire lifts guidance; silent on M&A buzz

Shares in Shire ( LON:SHP ) were given a shot in the arm after the drugmaker lifted its profit guidance and unveiled the acquisition of Australian biotech Fibrotech. First quarter revenues were up 18% at US$1.35bn, with non-GAAP earnings per share up ... [Published Proactiveinvestors United Kingdom RSS feed - May 01 2014]

Quotes

"This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature"
...5bn (£877m) and upgraded profit targets for the year as its chief executive Flemming Ornskov called the performance "a testament to the value AbbVie sees in our company"

More Content

All (8) | News (6) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
PHARM: Is That a Crack Forming in Cinryze’s Uni... [Published Noodls - Aug 29 2014]
AbbVie: Growth Story Or Patent Expiration Night... [Published Seeking Alpha - Aug 28 2014]
Emerging Pharma Leaders: Susanne Heinzinger [Published Pharmaceutical Executive - Aug 14 2014]
US drugs giant finally seals £32bn takeover of ... [Published The Independent - Jul 19 2014]
Shire lifts guidance; silent on M&A buzz [Published Proactiveinvestors United Kingdom RSS feed - May 01 2014]
Shire delivers a strong start to 2014 and incre... [Published Shire Pharmaceuticals - May 01 2014]
Rarefied Air of Rare Disease Drug Pricing [Published The Big Red Biotech Blog - Feb 20 2014]
Is This Analyst Wrong About Halozyme? [Published Wall St. Cheat Sheet - Jan 27 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Rarefied Air of Rare Disease Drug Pricing [Published The Big Red Biotech Blog - Feb 20 2014]
BioMarin has set the price for its newly approved drug Vimizim, a treatment for Moquito A syndrome, at $380,000 per year. At that price, it expects to garner about $500 M in annual sales and the drug clocks in with the 3rd highest overall drug price. ...
Is This Analyst Wrong About Halozyme? [Published Wall St. Cheat Sheet - Jan 27 2014]
Every once in a while, there is an event that makes investors scratch their heads. While most investors don’t base their investing decisions solely off sell-side upgrades/downgrades, it is still interesting to read them in order to perhaps gain ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.